These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6538503)

  • 81. Management of non-small-cell cancer.
    Soukop M
    Recent Results Cancer Res; 1984; 92():79-88. PubMed ID: 6204364
    [No Abstract]   [Full Text] [Related]  

  • 82. Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.
    Howman R; Thakerer A; Pitman M; Ding N; Thompson PA; Khot A; Harrison SJ
    Leuk Lymphoma; 2010 Dec; 51(12):2299-302. PubMed ID: 20929329
    [No Abstract]   [Full Text] [Related]  

  • 83. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.
    Raje N; Powles R; Kulkarni S; Milan S; Middleton G; Singhal S; Mehta J; Millar B; Viner C; Raymond J; Treleaven J; Cunningham D; Gore M
    Br J Haematol; 1997 Apr; 97(1):153-60. PubMed ID: 9136958
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
    Costa LJ; Abbas J; Ortiz-Cruz KL; Kang Y; Stuart RK
    Eur J Haematol; 2012 Nov; 89(5):432-4. PubMed ID: 22971164
    [No Abstract]   [Full Text] [Related]  

  • 85. The current status and future prospects of treatment for multiple myeloma.
    Durie BG; Salmon SE
    Clin Haematol; 1982 Feb; 11(1):181-210. PubMed ID: 6176381
    [No Abstract]   [Full Text] [Related]  

  • 86. Myeloma therapy.
    Brandes LJ; Israels LG
    Lancet; 1992 Apr; 339(8799):992. PubMed ID: 1348824
    [No Abstract]   [Full Text] [Related]  

  • 87. Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patients.
    Heyll A; Söhngen D; Kobbe G; Schneider P; Bauser U; Thiele KP; Wehmeier A; Südhoff T; Quenzel EM; Rieth C; Wernet P; Fischer J; Frick M; Aul C
    Leukemia; 1997 Dec; 11 Suppl 5():S32-4. PubMed ID: 9436936
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Salvage treatment for patient with multiple myeloma refractory to alkylating agents.
    Gomez GA; Han T; Ozer H; Henderson ES
    Med Pediatr Oncol; 1985; 13(6):325-9. PubMed ID: 4046971
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Importance of immunological and cytochemical studies of the peripheral blood lymphocytes in myeloma patients during polychemotherapy].
    Golenkov AK; Andreeva OK; Zlatkina AR; Cheredeev AN
    Gematol Transfuziol; 1984 Feb; 29(2):19-22. PubMed ID: 6608470
    [No Abstract]   [Full Text] [Related]  

  • 90. [Rheologic and hemocoagulation parameters in patients with multiple myeloma during therapy].
    Bessmel'tsev SS; Katsadze IuL; Abdulkadyrov KM; Zamotina TB
    Gematol Transfuziol; 1992 Mar; 37(3):19-23. PubMed ID: 1516794
    [No Abstract]   [Full Text] [Related]  

  • 91. Multiple myeloma.
    Oken MM
    Med Clin North Am; 1984 May; 68(3):757-87. PubMed ID: 6379340
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Multiple myeloma with high tumour mass. Treatment with high-dose methylprednisolone, cyclophosphamide and vindesine.
    van Dobbenburgh OA; Halie MR; Piersma H; Marrink J; Ockhuizen T; Nieweg HO
    Eur J Cancer Clin Oncol; 1984 Mar; 20(3):437-9. PubMed ID: 6538503
    [No Abstract]   [Full Text] [Related]  

  • 93. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
    Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
    [No Abstract]   [Full Text] [Related]  

  • 94. Vindesine in refractory multiple myeloma.
    van der Lelie H; Monasch E; Pegels HG; von dem Borne AE
    Cancer; 1986 Jan; 57(2):226-9. PubMed ID: 3942957
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Vindesine therapy in melphalan-resistant multiple myeloma.
    Houwen B; Ockhuizen T; Marrink J; Nieweg HO
    Eur J Cancer (1965); 1981 Feb; 17(2):227-32. PubMed ID: 7262159
    [No Abstract]   [Full Text] [Related]  

  • 96. Progress report on vindesine treatment of melphalan-resistant multiple myeloma.
    van Dobbenburgh OA; Houwen B; Halie MR; Marrink J; Ockhuizen T; Nieweg HO
    Eur J Cancer Clin Oncol; 1983 Jun; 19(6):861-2. PubMed ID: 6683653
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.